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Abstract 
Aim 
Heart failure with preserved ejection fraction (HFpEF) is associated with increased 
sympathetic nervous system (SNS) tone. Attenuating the SNS with renal denervation (RD) 
might be helpful and there are no data currently in humans with HFpEF. 
 
Methods and Results 
In this single-centre, randomised, open-controlled study we included 25 patients with HFpEF 
(preserved left ventricular (LV) ejection fraction, left atrial (LA) dilatation or LV 
hypertrophy and raised B-type natriuretic peptide (BNP) or echocardiographic assessment of 
filling pressures). Patients were randomised (2:1) to RD with the Symplicity™ catheter or 
continuing medical therapy. The primary success criterion was not met in that there were no 
differences between groups at 12 months for Minnesota Living with Heart Failure 
Questionnaire score, peak oxygen uptake (VO2) on exercise, BNP, E/e’, LA volume index or 
LV mass index. A greater proportion of patients improved at three months in the RD group 
with respect to VO2 peak (56% vs 13%, P=0.025) and E/e’ (31% vs 13%, P=0.04). Change in 
estimated glomerular filtration rate was comparable between groups. Two patients required 
plain balloon angioplasty during the RD procedure to treat renal artery wall oedema. 
 
Conclusion 
This study was terminated early due to difficulties in recruitment and was underpowered to 
detect whether RD improved the endpoints of: quality of life, exercise function, biomarkers 
and left heart remodelling. The procedure was safe in patients with HFpEF though two 
patients did require intra-procedure renal artery dilatation. 
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Introduction 
Heart failure with preserved ejection fraction (HFpEF) is associated with significant 
morbidity and mortality. There is currently no effective treatment despite trials of various 
interventions.1 The sympathetic nervous system (SNS) is a potential target. 
 
Activity of the sympathetic nervous system (SNS) is elevated in patients with heart failure 
and it has deleterious effects on the heart, peripheral vasculature, kidneys and skeletal 
muscle.2-7 The majority of this evidence relates to heart failure with reduced ejection fraction 
(HFrEF).7 In patients with heart failure with preserved ejection fraction (HFpEF) there is also 
limited  evidence of raised SNS activity as measured by heart rate variability,4, 5 serum 
noradrenaline levels3, 6 and muscle sympathetic nerve activity.2, 8 A dose-response 
relationship has been demonstrated in patients with HFpEF, such that those with greater 
sympathetic tone have more symptoms, a lower exercise capacity and higher natriuretic 
peptide levels.4, 9 However, treatments known to attenuate the SNS have so far failed to 
improve outcomes in HFpEF.1 
 
Trans-catheter renal denervation (RD) is an investigational technique that can reduce the 
activity of the SNS.10, 11 In animal models of HFrEF, RD has been shown to improve 
natriuresis, diuresis, and cardiac and renal function, which are important endpoints in HFpEF 
as well.11, 12 Furthermore, in patients with hypertension, RD reduces left ventricular (LV) 
mass, stiffness and filling pressures, which are common pathological features of HFpEF.13 
Currently, there are no validated animal models of HFpEF precluding clinical studies to 
determine the effects of RD. 
 
With this background and the current lack of available treatment options in HFpEF, we have 
tested the hypothesis that RD will improve haemodynamic and functional outcomes in 
patients with HFpEF. 
 
Methods 
Study Design 
The renal denervation in HFpEF (RDT-PEF) trial was a phase II, single-centre, prospective, 
randomised, controlled, open-label and blinded end point trial. It was investigator initiated 
and funded by the National Institute of Health Research Cardiovascular Biomedical Research 
Unit of Royal Brompton Hospital and Imperial College, London. Ethical approval for the 
study was granted by the National Research Ethics Service. All patients provided written 
informed consent. The trial was registered at clinicaltrials.gov: NCT01840059. 
 
Study Patients 
Eligible patients were 18-85 years of age and fulfilled the criteria in Table 1 (further details in 
the supplementary material online). 
 
The protocol was amended four months after the start of the trial to ensure adequate 
recruitment rate. This removed the requirement of previous heart failure hospitalisation and 
amended the EF threshold to >40% for trial inclusion (November 2013). 
 
Randomisation 
The trial used computer-generated randomisation (2:1; RD:control). Because this was a safety 
and mechanistic study and because there was limited experience of RD in patients with heart 
failure and none in patients with HFpEF, there was no clinician or patient blinding.12 Instead 
end points were analysed by observers blinded to patient allocation. 
 
Study Procedures 
A detailed description of the methods is provided in the supplementary material online. RD 
was performed using the Symplicity™ (Medtronic) single-electrode catheter. In all cases this 
was performed by one of two operators with two years prior experience of RD.  Patients 
randomised to medical therapy were followed-up in the same way at three and 12 months 
after randomisation (supplementary material Table S1). 
 
Efficacy Endpoints 
The endpoints reflected the multiple pathways that are abnormally activated in HFpEF 
covering symptoms, functional status, biomarkers and cardiac remodelling: The Minnesota 
Living with Heart Failure Questionnaire (MLWHFQ); peak treadmill exercise oxygen uptake 
(VO2 peak); B-type natriuretic peptide (BNP); E/e’ (ratio of early mitral outflow velocity to 
average of medial and lateral mitral annular tissue velocity); left atrial volume index (LAVi 
from cardiac magnetic resonance (CMR)) and left ventricular mass index (LVMi from 
CMR).  
 
The primary trial success criterion was defined a priori as an improvement in at least three of 
the six endpoints at 12 months of follow-up, without deterioration in any at P<0.2. The use of 
this probability threshold has precedent from a previous heart failure trial 14 and is supported 
by the Cardiovascular Cell Therapy Research Network.15 The risk of excessively inflating a 
type I error is reduced by the requirement of concordant improvements in all efficacy 
parameters without worsening of others.  
 Secondary endpoints included a composite score at the individual patient-level whereby each 
patient’s baseline value was compared with their 3 and 12-month value across the six primary 
end points and the patients’ responses were scored as: +1 for improvement, -1 for 
deterioration and 0 for no change using the thresholds detailed in the sample size.14  
 
Finally, to explore the effects of RD on sympathetic tone, meta-iodo-benzyl-guanidine 
(mIBG) scintigraphy was performed at baseline and 12 months. This technique permitted the 
quantification of cardiac sympathetic nerve activity using two derived parameters: washout 
rate and heart-mediastinum ratio (HMR). Patients with a higher washout rate (indicative of 
higher adrenergic drive) and lower late HMR (indicative of neuronal function including 
uptake and release of mIBG) have a worse prognosis in heart failure.16 Random plasma 
noradrenaline (the key neurotransmitter of the SNS) and 24 hour urine noradrenaline analyses 
were also undertaken. 
 
Safety Endpoints 
Safety endpoints included vascular access complications, deterioration in eGFR by >30% 
from baseline and renal artery injury requiring intervention. Renal artery magnetic resonance 
angiography (MRA) was completed at baseline and 12 months follow-up, to exclude new 
renal artery stenosis. 
 
Statistical analysis 
A sample size of 12 vs. 24 (control vs. RD) would have 85% power to detect an improvement 
of three or more endpoints with no significant deterioration in any using independent samples 
statistical tests to compare paired longitudinal differences using a threshold of P<0.2.17 
Clinically relevant changes in the outcomes and their standard deviations (SD) were taken 
from other studies as: ∆MLWHFQ 10 (SD 13);18 ∆VO2 peak  1.5 ml/kg/min (SD 2.5);18 
∆BNP 50ng/l (SD 130);19 ∆E/e’ 2 (SD 3);19 ∆LAVi 4 ml/m2 (SD 4);18 ∆LWMi 5 g/m2 (SD 
11).13 A correlation of 0.2 was assumed between the endpoints. After accounting for expected 
patient attrition we calculated a requirement to enrol 50 patients. 
 
Continuous variables are presented as mean±SD and compared using the t-test and analysis 
of variance. Non-normally distributed data are presented as median (quartile 1, quartile 3) 
and compared using the Mann-Whitney U test. Categorical data are presented as counts and 
percentages and compared using the chi-square test. A general linear model was also used to 
compare changes in the six primary endpoints between the two groups using baseline values 
as covariates and is presented as analysis of co-variance (ANCOVA) probability values.  
 
For all secondary analyses a P value <0.05 was considered statistically significant. SPSS 
(IBM v20) was used to perform the statistical analyses.  
 
Results 
Study Patients 
A total of 25 patients were randomised between July 2013 and December 2014 before the 
trial was stopped because of difficulty in recruitment despite nationwide screening (Figure 1). 
Baseline characteristics are shown in Table 2. Sixteen of the 25 patients (64%) had 
previously been admitted with decompensated heart failure within the preceding 24 months. 
Right and left heart catheterisation data are presented in supplementary material online Table 
S2. Fifteen of the 17 patients who were allocated to the RD arm had invasive evidence of 
raised left ventricular filling pressures at rest (either pulmonary capillary wedge pressure 
(PCWP) >15mmHg or left ventricular end-diastolic pressure (LVEDP) >16mmHg). All 
patients had an EF >50% on CMR. 
 
Efficacy Endpoints 
At 12 months follow-up the primary trial success criteria were not met and there were no 
significant changes across any of the six efficacy endpoints (Figure 2, supplementary material 
online Table S3). 
 
On secondary analysis, there was an improvement in the composite efficacy score at the 3 
months in the RD group compared with control (P=0.018) but not at 12 months (P=0.921) 
(Figure 3). This signal for an early effect was driven by a greater proportion of patients that 
improved by the pre-specified clinically significant amount in the RD group than in the 
control group with respect to VO2 peak (56% vs. 13%, P=0.025) and E/e’ (31% vs. 13%, 
P=0.04) (Figure 2).  
 
Safety and hospital admissions 
There were no deaths, strokes or myocardial infarctions during the course of the study. Two 
patients in the RD group had more than 30% reduction in eGFR at 12 months compared with 
baseline. There was no evidence of new renal artery stenosis on MRA in these patients. The 
median change in eGFR at 12 months was not different between the two study groups (-3 
ml/min/1.73m2 [-11, 3] vs. +4 ml/min/1.73m2 [-8, 5], RD vs. control, P=0.318). 
 
There were no femoral artery complications. Two patients developed intense renal artery 
spasm/oedema during RD that persisted for 20 minutes after intra-arterial nitrate and were 
further treated with low pressure angioplasty (without stent deployment), with a visually 
satisfactory result. These vessels were patent at 12 months by MRA and both patients had 
stable renal function.  
 
Three patients developed progression of existing renal artery atheroma that did not require 
intervention (one in the RDT group, two in the control group). Three patients were admitted 
with decompensated heart failure (two in the RDT group, one in the control group). Two 
patients underwent coronary revascularisation between the three and 12 months (one in each 
group). 
 
Number and distribution of ablations 
The number and location of successful ablations are detailed in the supplementary material 
online Table S4. All patients had a minimum of four (median 5) successful ablations to each 
attempted artery. No ablation was possible to the left renal artery of one patient because of an 
acute angle of origin and inability to achieve a stable guide catheter position. Twelve patients 
had incomplete circumferential ablations, whereby it was not possible to apply 
radiofrequency energy to all four quadrants successfully. 
 
The five patients who received anatomically complete denervation had no greater 
improvements at three month or 12 month follow-up compared with the 12 patients who did 
not (supplementary material online Table S5). 
 
Medication Changes 
There were no significant differences between the proportions of patients who had their 
cardiac medications (limited to angiotensin converting enzyme inhibitors, angiotensin 
receptor blockers, beta-blockers, alpha-blockers, diuretics, aldosterone antagonists, calcium-
channel blockers and digoxin) altered in either allocation group (supplementary material 
online Table S6).  
 
Blood pressure and heart rate 
At baseline, no patients had 24 hour ambulatory blood pressures greater than 150/90 mmHg. 
Eight patients had average pressures greater than 135/85 mmHg. There was no difference 
between groups at 12 months with respect to change in 24 hour ambulatory systolic blood 
pressure [-2.4 ± 9.7 vs. +1.3 ± 9.4mmHg, P=0.410 (RD vs. control)] or 24 hour mean heart 
rate [-3.4 ± 7.2 vs. +1.2 ± 6.4 beats-per-minute , P=0.162 (RD vs. control)]. 
 
Autonomic Assessments 
At baseline, 22 patients had evidence of abnormal sympathetic nerve activity: 18 patients had 
a late heart:mediastinum (HMR) of <1.6,20 19 had a cardiac wash-out of ≥ 27%21 on cardiac 
mIBG imaging and 12 had a plasma noradrenaline of >3.50 nmol/L (upper limit of normal 
for our laboratory). RD did not change any of the makers of sympathetic tone (Table 3). 
There was no difference in the change of autonomic parameters between patients who 
received anatomically complete RD compared with those who did not (supplementary 
material online, Table S5). 
 
Discussion 
This is the first report of a randomised controlled trial examining the role of RD in patients 
with HFpEF. The primary efficacy endpoint was not met and there were no significant 
improvements with RD with respect to heart failure symptoms, peak VO2 on exercise, BNP, 
E/e’ on echocardiography, left atrial volume index or left ventricular mass index at 12 
months. However, it would be premature to conclude that RD is ineffective in HFpEF for the 
following reasons: 
 
Firstly, the study was underpowered to detect a difference (85% power required a sample size 
of 36 patients, compared with 25 actually recruited) and hence is exposed to type II error. 
Although it might have been ambitious for a single-centre to recruit more patients, eleven 
heart failure units were involved in identifying patients for this study. Figure 1 shows why 
this study was underpowered.  Of 10,228 patients with a diagnosis of heart failure screened, 
124 met the study entry criteria. The reasons for this discrepancy have been discussed 
previously.22 Approximately 80% of candidates were excluded because of EF ≤ 40 or < 50% 
(depending on timing before or after modification of inclusion criteria). Of the remainder, 
approximately 90% were excluded because of age ≥ 85 years, significant valve disease or 
eGFR <45 ml/min/1.73m2 (supplementary material online, Figure S7). It is likely that 
stringent eligibility criteria coupled with screening restricted to cardiology clinics and heart 
failure admissions have made HFpEF a rare condition. A potential method of facilitating 
future trials is the establishment of national and international heart failure networks capable 
of diagnosing and identifying such patients. It might be possible to achieve adequate power 
by pooling our dataset with future trials of renal denervation for HFpEF if similar methods 
are adopted.  
 
Secondly, it is possible that the Symplicity™ catheter is ineffective at ablating renal 
innervation.  This has been discussed as a possible explanation for the unexpected results of 
the SYMPLICITY HTN-3 trial. In the absence of a marker of successful denervation, we 
used several surrogate markers of sympathetic tone, including mIBG scintigraphy. Despite 
not forming part of the eligibility criteria all but three patients had evidence of elevated SNS 
activity at baseline, however, RDT failed to attenuate any of the surrogate markers. 
Surprisingly, there was a non-significant trend that patients allocated to control had an 
improvement in the myocardial noradrenaline concentration (marker of sympathetic nerve 
integrity) whereas those who received RDT did not change. 
 
SYMPLICITY HTN-3 used the number of ablations applied and their completeness 
(covering all four quadrants) as a marker of quality of renal denervation. In that trial, a 
complete ablation was possible in only 19/364 (5.2%) of patients and these patients 
experienced the largest reduction in blood pressure.23 In the RDT-PEF trial, 5/17 (29.4%) 
patients received a four-quadrant ablation and we found no concordant changes in any of the 
primary endpoints compared with patients who did not receive complete ablation. It is 
possible that newer multi-electrode catheters might more readily achieve circumferential 
ablation pattern.10  
 
New findings on human renal nerve anatomy emerged during the conduct of the RDT-PEF 
trial suggesting that the sympathetic nerves approximate more closely to the distal artery as 
they pass from the aorta to the renal hilum.24 With this knowledge, we might preferentially 
have targeted the distal artery with a greater likelihood of ablating more nerves.25 
 
In secondary analyses there was a statistically significant trend improvement at three months 
in peak VO2 and E/e’ (Figure 2 &3), but the improvement was not sustained at 12 months. 
There are three possible explanations for this discrepancy. The first consideration is the 
Hawthorne effect, whereby patients who are pleased to be allocated to the RD group might 
make more effort in the cardiopulmonary exercise test thereby increasing the peak VO2.
26 It 
is likely that this bias would wane with time. Alternatively, the changes seen at three months 
might represent a type I error, where a significant difference is seen when one does not truly 
exist. The final possibility is sympathetic nerve regrowth, i.e. the improvements at three 
months were genuine. In sheep denervated with the Symplicity™ catheter, functional and 
anatomical regeneration of the afferent and efferent sympathetic nerves was seen at 11 
months.27 These findings reinforce the importance of blinding and staged analyses to look for 
early and late benefit.  
 
Consistent with the broader literature, which almost exclusively pertains to the Symplicity™ 
catheter, RD in patients with HFpEF appears safe up to 12 months of follow-up. However, 
the procedure is not without risk, with two patients requiring balloon angioplasty to treat 
intense vessel spasm/oedema, a complication which is usually treated with intra-arterial 
nitrate alone. Our decision to intervene on these patients was based upon the severity of the 
vessel reaction (>95% reduction in luminal diameter) and persistence (> 20 minutes); the 
requirement of balloon angioplasty to treat severe renal artery oedema/spasm following RD 
has been reported previously.28 Two other patients had a decline in eGFR>30%; further 
clinical follow-up data were available to us and these patients’ eGFR recovered to pre-
randomisation levels after completing treatment for fluid overload. It is important not to 
automatically extrapolate safety data established in the resistant hypertension population to 
an HFpEF cohort, which tends to be older and with more co-morbidities. 
  
The role of RD in the treatment of heart failure (regardless of ejection fraction) remains 
unclear. There exist many uncertainties, firstly- with the technology (multi-electrode versus 
single electrode systems) and how best to apply it (number and location of ablations in the 
renal artery); secondly- with trial design and whether sham-blinding should be mandatory; 
and thirdly, with endpoint selection particularly in phase II heart failure studies, where an 
ideal single surrogate endpoint does not exist.15 Finally, until an approach to accurately 
quantify the effects of RD on afferent and efferent renal sympathetic nerves is developed, it 
will remain difficult for future phase II studies to show a ‘dose-response’ effect, which will 
limit the credibility of any findings. 
 
Limitations 
The strengths of the RDT-PEF trial are that it is randomised and controlled and is the first to 
present data on patients with HFpEF exposed to RD. It is a single centre experience and 
hence its results may not be generalizable. Furthermore the trial findings are subject to bias as 
it was a non-blinded trial without a sham procedure. Efforts were undertaken to address this 
by having observers blinded to allocation analyse the collected data. This is likely to avoid 
most of the bias reported in the earlier trials of RDT in resistant hypertension but our trial 
remains susceptible to bias in the subjective endpoints such as symptom questionnaires.9, 26 
Another potential bias is that adherence to prescribed medications may have varied 
differently during the course of the study between the two treatment groups. This was 
particularly problematic in the unblinded studies of RD in resistant hypertension.26 In our 
HFpEF population, however, the impact of this limitation is likely to be minimal because 
none of our patients had resistant hypertension and no drugs have been shown to offer 
persistent benefit in HFpEF, hence changes in adherence should not greatly affect our heart 
failure related endpoints. The study used a novel trial success criterion based upon multiple 
primary endpoints; we and others believe that the measure of success of a phase II clinical 
study should not hinge upon achievement of statistical significance for a small number of 
primary end-points (this is how phase III studies are designed) but rather to provide a broader 
mechanistic insight by choosing a selection of endpoints addressing different categories of 
effects or domains without being overly concerned with suppressing the likelihood of false-
positive findings.15 Indeed no single endpoint can adequately capture the totality of the 
patient’s experience with HFpEF.15, 29    
 
Conclusions 
Renal denervation was safe, though not without complication (two patients required renal 
artery dilatation intra-procedurally), in this cohort of patients with HFpEF. No significant 
effect of RD was seen on multiple endpoints encompassing quality of life, exercise function, 
biomarkers and cardiac remodelling, though the study was underpowered for these. A 
possible signal of effect was seen at three months but this was not sustained at 12 months. A 
larger study is required, which would benefit from a co-ordinated effort across multiple heart 
failure networks to overcome the challenges in recruitment, and the use of multiple-electrode 
catheter systems. 
 
Figure Legends: 
Figure 1: Patient flow chart for the RDT-PEF study. No.- number of; HHF- admissions to 
hospital with heart failure; RBH: Royal Brompton Hospital; HF: heart failure 
 Figure 2: Primary efficacy endpoints for the RDT-PEF trial 3 and 12 months. The 
brown dotted lines represent the threshold for a clinically significant change. MLWHFQ- 
Minnesota Living with Heart Failure Questionnaire; Peak VO2- maximum oxygen uptake on 
exercise treadmill; BNP- B-type natriuretic peptide; LAVi- left atrial volume index; LVMi- 
left ventricular mass index. 
 
Figure 3: Changes in composite patient score. Numbers in each filled circle correspond to 
an individual patient. Summary lines represent mean with standard error. P values derived 
from independent samples t-test. 
 Table 1: RDT-PEF eligibility criteria. 
 
* Criteria that were revised following a protocol amendment. MDRD- Modification of Diet in 
Renal Disease criteria; eGFR- estimated glomerular filtration rate; LVED- left ventricular 
Inclusion Criteria Exclusion Criteria 
NYHA II-III eGFR <45ml/min/1.73m2 (MDRD) 
Ejection Fraction ≥50%* Contraindication to CMR 
Non-dilated left ventricle (LVEDD <60mm 
or LVESD <45mm  
Cardiomyopathy (constrictive, restrictive, 
dilated, previously documented EF <40%) 
Either: 
 Dilated left atrium (diameter >38mm 
(women)/>40mm (men) or area> 20cm2) 
or,  
 Left ventricular hypertrophy (wall 
thickness ≥12mm)  
Significant valvular disease (moderate or 
worse aortic regurgitation/stenosis or mitral 
stenosis; or severe mitral regurgitation) 
Either: 
 E/e’ (lateral)>10, E/e’ (septal)>15 [7] or, 
 BNP ≥35 ng/L 
Renal artery diameter >4mm and treatable 
renal artery segment <20mm 
Admission with heart failure in previous 24 
months* 
Acute coronary syndrome or stroke in 
previous 6 months 
end diastolic dimension; LVESD- left ventricular end-systolic dimension; BNP- B-type 
natriuretic peptide; EF- ejection fraction; CMR- cardiac magnetic resonance 
Table 2: Baseline characteristics of the RDT-PEF population. 
 Total (n=25) RD (n=17) Control (n=8) P (RD vs Control) 
Demographics 
Age 74.3 ± 6.1 74.1 ± 6.8 74.6 ± 4.8 0.852 
Male 15 (60%) 11 (64.7%) 4 (50.0%) 0.667 
Ethnicity 
  Caucasian 
  Black 
  Asian 
 
19 (76%) 
1 (4%) 
5 (20%) 
 
11 (65%) 
1 (6%) 
5 (29%) 
 
8 (100%) 
0 (0%) 
0 (0%) 
0.156 
BMI (kg/m2) 30.6 ± 5.5 30.5 ± 4.6 30.8 ± 7.4 0.911 
BSA (m2) 2.0 ± 0.2 2.0 ± 0.2 2.0 ± 0.3 0.897 
Past Medical History 
Hypertension 18 (72%) 14 (82.4%) 4 (50%) 0.156 
Diabetes 10 (40%) 8 (47.1%) 2 (25%) 0.402 
CVA 1 (4%) 1 (5.9%) 0 (0.0%) 1.000 
CHD 6 (24%) 5 (29.4%) 1 (12.5%) 0.624 
AF 15 (60%) 10 (58.8%) 5 (62.5%) 1.000 
Cardiac Surgery 7 (28%) 4 (23.5%) 3 (37.5%) 0.640 
OSA 4 (16%) 3 (17.6%) 1 (12.5%) 1.000 
COPD 6 (24%) 4 (23.5%) 2 (25%) 1.000 
Cancer 4 (16%) 4 (23.5%) 0 (0.0%) 0.269 
Medications 
ACEi/ARB 23 (92%) 16 (94.1%) 7 (87.5%) 1.000 
Alpha-blockers 4 (16%) 2 (11.8%) 2 (25%) 0.570 
Beta-blockers 18 (72%) 12 (70.6%) 6 (75%) 1.000 
CC-blockers 8 (32%) 7 (41.2%) 1 (12.5%) 0.205 
Loop diuretics 21 (84%) 16 (94.1%) 5 (62.5%) 0.081 
Spironolactone 6 (24%) 6 (35.3%) 0 (0.0%) 0.129 
Clinical Assessments 
NYHA Class 
II 
III 
 
14 (56%) 
11 (44%) 
 
10 (58.8%) 
7 (41.2%) 
 
4 (50%) 
4 (50%) 
1.000 
A SBP (mmHg) 125 ± 13.9 128 ± 15.0 120 ± 9.7 0.190 
A DBP (mmHg) 71 ± 8.2 71 ± 9.4 71 ± 5.1 0.866 
A HR (b/m) 73 ± 12.2 73 ± 13.7 72 ± 9.0 0.781 
Laboratory Tests 
Haemoglobin 
(g/dl) 
131 ± 16 129 ± 16.4 135 ± 15.5 0.455 
eGFR 
(ml/min/1.73m2) 
61 (49.5-67.5) 61 (50.5-68) 61 (48.5-67.3) 0.887 
Primary Efficacy Endpoints 
MLWHFQ 47 (25-54) 48 (27-56) 28 (25-50) 0.351 
VO2 Peak 
(ml/kg/min) 
15.6 ± 3.6 14.7 ± 3.3 17.5 ± 3.8 0.073 
BNP (ng/l) 184 (122-287) 210 (137-354) 149 (99-205) 0.124 
Average E/e’  13.8 ± 5.3 13.6 ± 5.9 14.4 ± 3.9 0.747 
LAVi (ml/m2) 62.3 ± 28.1 62.8 ± 29.2 61.3 ± 21.7 0.905 
LVMi (g/m2) 63.4 ± 10.4 62.9 ± 11.4 64.6 ± 7.1 0.653 
Data are presented as mean ± standard deviation or median (quartile 1, quartile 3). BMI- 
body mass index; BSA- body surface area; CVA- cerebrovascular accident; CHD- coronary 
heart disease; AF- atrial fibrillation; OSA- obstructive sleep apnoea; COPD- chronic 
obstructive pulmonary disease; MLWHFQ- Minnesota Living with Heart Failure 
Questionnaire; NYHA- New York Heart Association; A- ambulatory; SBP- systolic blood 
pressure; DBP- diastolic blood pressure; HR- heart rate; ACEi- angiotensin converting 
enzyme inhibitor; ARB- angiotensin receptor blocker; CC- calcium channel; eGFR- 
estimated glomerular filtration rate; BNP- brain-type natriuretic peptide; VO2- oxygen 
uptake; LAVi- left atrial volume index; LVMi- left ventricular mass index 
Table 3: Summary of autonomic assessments in the RDT-PEF trial. 
 RD Control Base
line 
Change from baseline 
 Base
line  
3 
Mo
nths  
12 
Mo
nths  
Base
line  
3 
Mo
nths  
12 
Mo
nths  
RD 
vs 
Con
trol 
3 Months 12 Months 
P R
D 
Con
trol 
P R
D 
Con
trol 
P 
Cardiac mIBG 
Early 
HMR 
1.61 
(1.50
,  
1.80) 
 1.58 
(1.4
5, 
1.77
) 
1.56 
(1.46
, 
1.72) 
 1.73 
(1.6
7, 
1.89
) 
0.66
9 
 +0.
01 
(-
0.1
3, 
0.1
0) 
+ 
0.00 
(-
0.01
, 
0.33
) 
0.1
66 
Late 
HMR 
1.49 
± 
0.18 
1.49 
± 
0.17  
1.52 
± 
0.19 
1.65 
± 
0.19 
0.73
0 
-
0.0
0  
± 
0.1
1 
+0.1
0  ± 
0.11 
0.0
59 
Washo
ut rate 
(%) 
36.7 
± 
15.2 
32.8 
± 
19.7 
33.0 
± 
16.6 
30.0 
± 
12.5 
0.59
1 
-
3.8  
± 
19.
1 
+0.8 
± 
8.8 
0.5
52 
Noradrenaline Assays 
Plasm
a 
(nmol/
l) 
3.91 
± 
1.29   
3.86 
± 
2.22 
3.87 
± 
1.58 
3.34  
± 
0.85 
4.25 
± 
2.29 
3.05 
± 
0.91 
0.27
0 
-
0.
05 
± 
2.
37 
+0.9
1  ± 
1.62 
0.3
13 
-
0.0
4 ± 
1.7
8 
-
0.03 
± 
0.91 
0.9
91 
24hr 
Urine 
(nmol/
24hr) 
248 
± 98 
 228 
± 
125 
245 
± 68 
 203 
± 41 
0.92
0 
 -28 
± 
36 
-20 
± 85 
0.7
62 
RD- renal denervation; HMR- heart-mediastinum ratio. Parametric data are presented as 
mean±standard deviation. Non-parametric data are presented as median (quartile 1, quartile 
3). 
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